COVID-19 Vaccines: Tolerance of Vaccination in Patients with Allergies.

IF 5.2 3区 医学 Q1 IMMUNOLOGY
Vaccines Pub Date : 2025-08-26 DOI:10.3390/vaccines13090904
Natalie Kogseder, Viktoria Puxkandl, Wolfram Hötzenecker, Sabine Altrichter
{"title":"COVID-19 Vaccines: Tolerance of Vaccination in Patients with Allergies.","authors":"Natalie Kogseder, Viktoria Puxkandl, Wolfram Hötzenecker, Sabine Altrichter","doi":"10.3390/vaccines13090904","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Due to the new COVID-19 vaccine types used in the COVID-19 vaccination program, significant levels of uncertainty and vaccine hesitancy arose due to fears about anaphylactic reactions, especially in patients with allergies. This study aimed to analyze how patients with significant allergies receiving specific immunotherapy (SIT) reacted to COVID-19 vaccines in real life. <b>Methods</b>: We assessed 57 patient charts of individuals with allergies receiving SIT for documented allergies, for their comorbidities, total IgE and tryptase levels, and Hospital Anxiety and Depression Scale (HADS) scores. Questionnaires regarding COVID-19 vaccination status and reported adverse reactions were analyzed. <b>Results</b>: Patients were more frequently male (58%) and had a mean age of 43 years, and the majority (60%) had already experienced an anaphylactic reaction in the past, most commonly to the allergen of the current SIT. In total, 93% received COVID-19 vaccinations. More than half of the patients (57%) reported at least one adverse reaction after COVID-19 vaccination. Out of these patients, 97% reacted in an unspecific way, with symptoms of general illness. One potential allergic reaction, classified as a grade 1 anaphylactic reaction, was documented. The patient with the potential allergic reaction was significantly more concerned before receiving the vaccination and had experienced possible allergic reactions to other vaccinations in the past. The remaining patients with unspecific reactions after vaccination had also experienced such adverse reactions in the past to other vaccinations. Antihistamine premedication was associated with fewer unspecific reactions after COVID-19 vaccination. <b>Conclusions</b>: Vaccinations in patients with significant allergies and prior anaphylactic reactions are, overall, safe. Prior allergic reactions after other vaccinations could be a potential risk for reaction after COVID-19 vaccinations, whereas antihistamine intake could be beneficial in reducing side effects after COVID-19 vaccinations in patients with allergies. Prospective studies on this topic are needed.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474330/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13090904","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Due to the new COVID-19 vaccine types used in the COVID-19 vaccination program, significant levels of uncertainty and vaccine hesitancy arose due to fears about anaphylactic reactions, especially in patients with allergies. This study aimed to analyze how patients with significant allergies receiving specific immunotherapy (SIT) reacted to COVID-19 vaccines in real life. Methods: We assessed 57 patient charts of individuals with allergies receiving SIT for documented allergies, for their comorbidities, total IgE and tryptase levels, and Hospital Anxiety and Depression Scale (HADS) scores. Questionnaires regarding COVID-19 vaccination status and reported adverse reactions were analyzed. Results: Patients were more frequently male (58%) and had a mean age of 43 years, and the majority (60%) had already experienced an anaphylactic reaction in the past, most commonly to the allergen of the current SIT. In total, 93% received COVID-19 vaccinations. More than half of the patients (57%) reported at least one adverse reaction after COVID-19 vaccination. Out of these patients, 97% reacted in an unspecific way, with symptoms of general illness. One potential allergic reaction, classified as a grade 1 anaphylactic reaction, was documented. The patient with the potential allergic reaction was significantly more concerned before receiving the vaccination and had experienced possible allergic reactions to other vaccinations in the past. The remaining patients with unspecific reactions after vaccination had also experienced such adverse reactions in the past to other vaccinations. Antihistamine premedication was associated with fewer unspecific reactions after COVID-19 vaccination. Conclusions: Vaccinations in patients with significant allergies and prior anaphylactic reactions are, overall, safe. Prior allergic reactions after other vaccinations could be a potential risk for reaction after COVID-19 vaccinations, whereas antihistamine intake could be beneficial in reducing side effects after COVID-19 vaccinations in patients with allergies. Prospective studies on this topic are needed.

Abstract Image

Abstract Image

Abstract Image

COVID-19疫苗:过敏患者的疫苗耐受性
背景:由于在COVID-19疫苗接种计划中使用了新的COVID-19疫苗类型,由于担心过敏反应,特别是过敏患者,出现了严重的不确定性和疫苗犹豫。本研究旨在分析现实生活中接受特异性免疫治疗(SIT)的严重过敏患者对COVID-19疫苗的反应。方法:我们评估了57例接受SIT治疗的过敏患者的病历,包括他们的合并症、总IgE和胰蛋白酶水平以及医院焦虑和抑郁量表(HADS)评分。对COVID-19疫苗接种状况和报告不良反应的问卷进行分析。结果:患者多为男性(58%),平均年龄为43岁,大多数(60%)过去已经经历过过敏反应,最常见的是对当前SIT的过敏原。总共有93%的人接种了COVID-19疫苗。超过一半的患者(57%)报告在COVID-19疫苗接种后至少发生一次不良反应。在这些患者中,97%的反应是非特异性的,具有一般疾病的症状。一个潜在的过敏反应,分类为1级过敏反应,记录在案。有潜在过敏反应的患者在接种疫苗前明显更关注,并且过去对其他疫苗可能有过敏反应。其余接种疫苗后出现非特异性反应的患者也曾在过去接种其他疫苗时出现过此类不良反应。抗组胺预用药与COVID-19疫苗接种后的非特异性反应较少相关。结论:对有明显过敏和既往过敏反应的患者接种疫苗总体上是安全的。先前接种其他疫苗后的过敏反应可能是COVID-19疫苗接种后反应的潜在风险,而过敏患者服用抗组胺药可能有助于减少COVID-19疫苗接种后的副作用。需要对这一主题进行前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信